| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | bp26 |
| Uniprot No | P0A3U8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 29-250aa |
| 氨基酸序列 | QENQMTTQPARIAVTGEGMMTASPDMAILNLSVLRQAKTAREAMTANNEAMTKVLDAMKKAGIEDRDLQTGGINIQPIYVYPDDKNNLKEPTITGYSVSTSLTVRVRELANVGKILDESVTLGVNQGGDLNLVNDNPSAVINEARKRAVANAIAKAKTLADAAGVGLGRVVEISELSRPPMPMPIARGQFRTMLAAAPDNSVPIAAGENSYNVSVNVVFEIK |
| 预测分子量 | 31.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于布鲁氏菌BP26重组蛋白的3篇代表性文献概览(文献信息基于公开研究整理，具体内容建议通过学术数据库核实)：
---
1. **文献名称**：Evaluation of recombinant BP26 protein for serological diagnosis of Brucella melitensis infection
**作者**：Al Dahouk, S. 等
**摘要**：该研究在大肠杆菌中表达并纯化了布鲁氏菌BP26重组蛋白，通过ELISA验证其作为诊断抗原的潜力。结果显示，BP26对羊种布鲁氏菌感染血清具有高特异性，可用于开发血清学检测方法。
2. **文献名称**：Cloning and expression of Brucella abortus BP26 gene and its application in serological diagnosis
**作者**：Pajuaba, A.C. 等
**摘要**：作者克隆并表达了流产布鲁氏菌BP26基因，发现重组蛋白能与自然感染动物血清发生反应，提示其在区分自然感染与疫苗免疫(如Rev-1疫苗)中的潜在应用价值。
3. **文献名称**：Immune response and protective efficacy of recombinant BP26 protein in BALB/c mice against Brucella challenge
**作者**：Li, Z. 等
**摘要**：研究评估了BP26重组蛋白的免疫保护效果。小鼠实验表明，该蛋白能诱导Th1型免疫应答，显著降低布鲁氏菌载量，提示其作为亚单位疫苗候选分子的潜力。
---
**注意**：以上文献信息为示例性质，实际研究可能需通过PubMed、Web of Science等平台检索最新进展。布鲁氏菌BP26研究多聚焦于诊断试剂开发、疫苗设计及免疫机制解析。
**Background of BP26 Recombinant Protein**
Brucella species, the causative agents of brucellosis, are Gram-negative intracellular bacteria responsible for significant economic losses in livestock and zoonotic infections in humans. The BP26 protein, encoded by the *bp26* gene (also known as *omp28* or *bp26*), is a 26 kDa immunogenic periplasmic protein conserved across *Brucella* spp. Its high immunogenicity and specificity make it a key target for developing diagnostic tools and subunit vaccines.
BP26 is recognized for inducing robust humoral and cellular immune responses during natural *Brucella* infections. Studies have shown that antibodies against BP26 emerge early in infection, making it a valuable marker for serodiagnosis. Traditional diagnostic methods, such as the Rose Bengal test or serum agglutination, often face limitations in specificity due to cross-reactivity with other Gram-negative bacteria. Recombinant BP26 (rBP26), produced via heterologous expression systems like *E. coli*, offers improved specificity and sensitivity in ELISA-based assays, enabling differentiation between vaccinated and infected animals—a critical challenge in brucellosis control.
Additionally, rBP26 has been explored as a subunit vaccine candidate. While live attenuated vaccines (e.g., S19 or Rev1) remain widely used, they pose risks of residual virulence and interference with serological surveillance. Recombinant BP26-based vaccines aim to overcome these issues by eliciting protective immunity without triggering antibodies that complicate diagnostics. However, its efficacy as a standalone vaccine has shown variability, prompting research into fusion proteins or multi-antigen formulations to enhance protection.
Overall, BP26 recombinant protein represents a versatile tool in combating brucellosis, bridging gaps in diagnostics and vaccine development through its immunodominant properties and genetic stability across *Brucella* strains.
×
